Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,21541781,t(1/2),"Macitentan was slowly absorbed and, at a dose of 300 mg, the t(1/2) (95% confidence interval, CI) was 17.5 h (14.1, 21.8).",Macitentan: entry-into-humans study with a new endothelin receptor antagonist. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21541781/),h,17.5,1769,DB08932,MACITENTAN
,21541781,t(1/2),"The t(1/2) of ACT-132577 (95% CI) was 65.6 h (53.1, 80.9).",Macitentan: entry-into-humans study with a new endothelin receptor antagonist. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21541781/),h,65.6,1770,DB08932,MACITENTAN
,34159557,apparent volume of distribution,The apparent volume of distribution was 34 L and clearance was 1.39 L/h.,A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34159557/),l,34,18895,DB08932,MACITENTAN
,34159557,clearance,The apparent volume of distribution was 34 L and clearance was 1.39 L/h.,A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34159557/),[l] / [h],1.39,18896,DB08932,MACITENTAN
,19765655,t(max),ACT-064992 revealed a slow absorption (median t(max) 8h) and a terminal half-life of approximately 13 h.,Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19765655/),h,8,20812,DB08932,MACITENTAN
,19765655,terminal half-life,ACT-064992 revealed a slow absorption (median t(max) 8h) and a terminal half-life of approximately 13 h.,Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19765655/),h,13,20813,DB08932,MACITENTAN
,19765655,t(max),"The pharmacokinetics of the metabolite ACT-132577, characterized by a t(max) of approximately 48 h and a terminal half-life of approximately 45 h, was not different between the two formulations.",Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19765655/),h,48,20814,DB08932,MACITENTAN
,19765655,terminal half-life,"The pharmacokinetics of the metabolite ACT-132577, characterized by a t(max) of approximately 48 h and a terminal half-life of approximately 45 h, was not different between the two formulations.",Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19765655/),h,45,20815,DB08932,MACITENTAN
,26363370,flow rate,"Plasma samples were processed with a protein precipitation using acetonitrile, followed by chromatographic separation using an Inertsil ODS-SP column (100×2.1mm, 3.5μm) under isocratic elution with a mobile phase consisting of acetonitrile and 0.2% formic acid at a flow rate of 0.3mL/min.",Simultaneous determination of macitentan and its active metabolite in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26363370/),[ml] / [min],0.3,94345,DB08932,MACITENTAN
,26363370,m/,"Quantification was operated in multiple reaction monitoring (MRM) mode using the transitions m/z 547.1→201.0 for macitentan, m/z 589.0→203.0 for ACT-132577, and m/z 380.5→243.3 for the IS (donepezil).",Simultaneous determination of macitentan and its active metabolite in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26363370/),,547.1,94346,DB08932,MACITENTAN
,26363370,m/,"Quantification was operated in multiple reaction monitoring (MRM) mode using the transitions m/z 547.1→201.0 for macitentan, m/z 589.0→203.0 for ACT-132577, and m/z 380.5→243.3 for the IS (donepezil).",Simultaneous determination of macitentan and its active metabolite in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26363370/),,201.0,94347,DB08932,MACITENTAN
,26363370,m/z,"Quantification was operated in multiple reaction monitoring (MRM) mode using the transitions m/z 547.1→201.0 for macitentan, m/z 589.0→203.0 for ACT-132577, and m/z 380.5→243.3 for the IS (donepezil).",Simultaneous determination of macitentan and its active metabolite in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26363370/),,589.0,94348,DB08932,MACITENTAN
,26363370,m/z,"Quantification was operated in multiple reaction monitoring (MRM) mode using the transitions m/z 547.1→201.0 for macitentan, m/z 589.0→203.0 for ACT-132577, and m/z 380.5→243.3 for the IS (donepezil).",Simultaneous determination of macitentan and its active metabolite in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26363370/),,203.0,94349,DB08932,MACITENTAN
,26363370,m/z,"Quantification was operated in multiple reaction monitoring (MRM) mode using the transitions m/z 547.1→201.0 for macitentan, m/z 589.0→203.0 for ACT-132577, and m/z 380.5→243.3 for the IS (donepezil).",Simultaneous determination of macitentan and its active metabolite in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26363370/),,380.5,94350,DB08932,MACITENTAN
,26363370,m/z,"Quantification was operated in multiple reaction monitoring (MRM) mode using the transitions m/z 547.1→201.0 for macitentan, m/z 589.0→203.0 for ACT-132577, and m/z 380.5→243.3 for the IS (donepezil).",Simultaneous determination of macitentan and its active metabolite in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26363370/),,243.3,94351,DB08932,MACITENTAN
,24906252,time to maximum plasma concentration [t(max)],The concentration-time profile of macitentan was characterized by slow absorption (median time to maximum plasma concentration [t(max)] 9-10 h) and slow elimination (mean elimination half-life [t ½] 11-15 h).,"Pharmacokinetic-pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24906252/),h,9-10,109058,DB08932,MACITENTAN
,24906252,elimination half-life [t ½],The concentration-time profile of macitentan was characterized by slow absorption (median time to maximum plasma concentration [t(max)] 9-10 h) and slow elimination (mean elimination half-life [t ½] 11-15 h).,"Pharmacokinetic-pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24906252/),h,11-15,109059,DB08932,MACITENTAN
,24906252,half-life,"ACT-132577 showed higher levels of exposure than macitentan, its mean half-life was 46-48 h, and it accumulated 7- to 12-fold.","Pharmacokinetic-pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24906252/),h,46-48,109060,DB08932,MACITENTAN
,32539916,total run time,The total run time for a single injection was within 10 min.,"Simultaneous LC-MS analysis of plasma concentrations of sildenafil, tadalafil, bosentan, ambrisentan, and macitentan in patients with pulmonary arterial hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32539916/),min,10,123308,DB08932,MACITENTAN
,26770447,m,"An electrospray ionization source was applied and operated in positive ion mode; multiple reactions monitoring (MRM) mode was used for quantification using target fragment ions m/z 546.9→200.6 for ACT-132577, and m/z 285.1→193.1 for IS.",Pharmacokinetic study of ACT-132577 in rat plasma by ultra performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26770447/),,285.1,144306,DB08932,MACITENTAN
,26770447,recovery,"Mean recovery of ACT-132577 in rat plasma ranged from 82.6% to 90.6%, matrix effect of ACT-132577 in rat plasma ranged from 101.4% to 115.2%.",Pharmacokinetic study of ACT-132577 in rat plasma by ultra performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26770447/),%,82.6,144307,DB08932,MACITENTAN
,26770447,recovery,"Mean recovery of ACT-132577 in rat plasma ranged from 82.6% to 90.6%, matrix effect of ACT-132577 in rat plasma ranged from 101.4% to 115.2%.",Pharmacokinetic study of ACT-132577 in rat plasma by ultra performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26770447/),%,90.6,144308,DB08932,MACITENTAN
,26770447,matrix effect,"Mean recovery of ACT-132577 in rat plasma ranged from 82.6% to 90.6%, matrix effect of ACT-132577 in rat plasma ranged from 101.4% to 115.2%.",Pharmacokinetic study of ACT-132577 in rat plasma by ultra performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26770447/),%,101.4,144309,DB08932,MACITENTAN
,26770447,matrix effect,"Mean recovery of ACT-132577 in rat plasma ranged from 82.6% to 90.6%, matrix effect of ACT-132577 in rat plasma ranged from 101.4% to 115.2%.",Pharmacokinetic study of ACT-132577 in rat plasma by ultra performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26770447/),%,115.2,144310,DB08932,MACITENTAN
,31875652,flow rate,A chromatographic separation was performed on a C18 column using a gradient of methanol-water containing 0.1% formic acid and 0.013% ammonium acetate and a flow rate of 0.5 ml/min.,"Simultaneous quantification of ambrisentan, macitentan and sitaxentan in human plasma using UPLC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31875652/),[ml] / [min],0.5,155373,DB08932,MACITENTAN
,23900878,tmax,"The multiple-dose pharmacokinetics of macitentan were dose-proportional and were characterized by a median tmax and apparent elimination half-life varying from 6.0 to 8.5 and 14.3 to 18.5 hours, respectively, for the different doses and minimal accumulation.","Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23900878/),h,6.0 to 8.5,181101,DB08932,MACITENTAN
,23900878,apparent elimination half-life,"The multiple-dose pharmacokinetics of macitentan were dose-proportional and were characterized by a median tmax and apparent elimination half-life varying from 6.0 to 8.5 and 14.3 to 18.5 hours, respectively, for the different doses and minimal accumulation.","Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23900878/),h,14.3 to 18.5,181102,DB08932,MACITENTAN
,23900878,half-life,"ACT-132577, a metabolite with lower potency than macitentan, had a half-life of about 48 hours and accumulated approximately 8.5-fold.","Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23900878/),h,48,181103,DB08932,MACITENTAN
,22458347,cumulative recovery,"Mean (± SD) cumulative recovery of radioactivity from faeces and urine was 73.6% (± 6.2%) of the administered radioactive dose, with 49.7% (± 3.9%) cumulative recovery from urine, and 23.9% (± 4.8%) from faeces.","Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22458347/),%,73.6,185832,DB08932,MACITENTAN
,22458347,cumulative recovery,"Mean (± SD) cumulative recovery of radioactivity from faeces and urine was 73.6% (± 6.2%) of the administered radioactive dose, with 49.7% (± 3.9%) cumulative recovery from urine, and 23.9% (± 4.8%) from faeces.","Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22458347/),%,49.7,185833,DB08932,MACITENTAN
,30725476,flow rate,"Chromatographic separation was performed on a reverse-phase C18 column (5 μm, 4.6 × 150 mm) with an isocratic mobile phase, which consisted of water containing 0.2% acetic acid-acetonitrile (90:10, v/v) at a flow rate of 1 mL/min.","A novel, rapid and sensitive UPLC-MS/MS method for the determination of macitentan in patients with pulmonary arterial hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30725476/),[ml] / [min],1,251346,DB08932,MACITENTAN
,30725476,Retention times,"Retention times were 1.97 and 1.72 min for macitentan and IS, respectively.","A novel, rapid and sensitive UPLC-MS/MS method for the determination of macitentan in patients with pulmonary arterial hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30725476/),min,1.97,251347,DB08932,MACITENTAN
,30725476,Retention times,"Retention times were 1.97 and 1.72 min for macitentan and IS, respectively.","A novel, rapid and sensitive UPLC-MS/MS method for the determination of macitentan in patients with pulmonary arterial hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30725476/),min,1.72,251348,DB08932,MACITENTAN
,30725476,recovery,"The lower limit of quantitation and average recovery values were determined as 1 ng/mL and 89.8%, respectively.","A novel, rapid and sensitive UPLC-MS/MS method for the determination of macitentan in patients with pulmonary arterial hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30725476/),%,89.8,251349,DB08932,MACITENTAN
